30例肝转移性神经内分泌肿瘤超声造影表现及微波消融治疗效果分析*

doi:10.3969/j.issn.1672-5069.2024.05.033

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (5): 777-780.doi: 10.3969/j.issn.1672-5069.2024.05.033

30例肝转移性神经内分泌肿瘤超声造影表现及微波消融治疗效果分析^*

吕莉, 刘苗, 周敏, 王波玲

710061 西安市西北妇女儿童医院医学超声中心(吕莉,刘苗);空军军医大学第一附属医院消化内科超声诊疗中心(周敏);消化内科(王波玲)

收稿日期:2023-11-02 出版日期:2024-09-10 发布日期:2024-09-09
通讯作者: 周敏,E-mail:870834923@qq.com
作者简介:吕莉,女,33岁,医学硕士,住院医师。E-mail:l15223117@163.com
基金资助:
^*陕西省科技厅重点研发计划项目(编号:2022ZDLSF04-04)

Contrast-enhanced ultrasound feature and short-term efficacy of microwave ablation in patients with neuroendocrine tumor liver metastases: An analysis of 30 cases

Lyu Li, Liu Miao, Zhou Min, et al

Department of Medical Ultrasound, Northwest Women's and Children's Hospital, Xi'an 710061, Shaanxi Province, China

Received:2023-11-02 Online:2024-09-10 Published:2024-09-09

摘要/Abstract

摘要： 目的观察肝转移性神经内分泌肿瘤超声造影(CEUS)表现特征,并观察在超声引导下微波消融(MWA)的治疗效果。方法 2017年1月～2022年1月空军军医大学第一附属医院收治的肝转移性NET患者30例,其中原发病灶来自结肠21例(70.0%)、胰腺7例(23.3%)和胃2例(6.7%)。均接受CEUS检查和在超声引导下行MWA治疗,随访。结果 30例肝转移性NET病灶CEUS检查开始增强时间(AT)、达峰时间(TTP)和消退时间(RT)分别为(17.2±3.5)s、(22.3±4.5)s和(40.9±13.1)s,病灶整体增强24例(80.0%),向心性增强6例(20.0%);病灶增强峰值表现为均匀增强、不均匀增强和环形增强分别为18例(60.0%)、8例(26.7%)和4例(13.3%);门静脉期呈轻度消退和明显消退分为为10例(33.3%)和20例(66.7%);病灶CEUS增强-消退模式包括快进快出、同进快出和慢进快出分别为15例(50.0%)、9例(30.0%)和6例(20.0%);在MWA治疗后,30例肝转移性NET病灶近期获得CR、PR、PD和SD分别为21例(70.0%)、4例(13.3%)、2例(6.7%)和3例(10.0%)。结论大多肝转移性NET来自胃肠道,在CEUS下呈整体增强或均匀增强,门静脉期则明显消退,以快进快出增强模式为主,难以与肝细胞癌鉴别。局部介入治疗后,可获得短期疗效。

关键词: 肝转移性神经内分泌肿瘤, 超声造影, 微波消融, 治疗

Abstract: Objective The aim of this study was to observe the contrast-enhanced ultrasound (CEUS) feature and short-term efficacy of microwave ablation (MWA) in patients with liver metastatic neuroendocrine tumors(LMNET). Methods 30 patients with LMNET arose from gastrointestinal tract were admitted to the First Affiliated Hospital, Air Force Military Medical University between January 2017 and January 2022, and all underwent CEUS check-up and MWA under US guidance. Results The arrival time, time to peak and resolution time by CEUS in the 30 patients with LMNET were (17.2±3.5)s, (22.3±4.5)s and (40.9±13.1)s, and the enhancement modes included global enhancement in 24 cases (80.0%) and centripetal enhancement in 6 cases (20.0%); at peak enhancement, the lesions showed uniform, heterogeneous and circular enhancement in 18 cases (60.0%), in 8 cases (26.7%) and 4 cases (13.3%); at portal vein phase, the lesions showed mild and obvious subsides in 10 cases (33.3%) and in 20 cases (66.7%); the CEUS enhancement patterns of the lesions included fast-in and fast-out, average-in and fast-out, slow-in and fast-out in 15 cases (50.0%), in 9 cases (30.0%) and 6 cases (20.0%); after intervention of MWA, the complete remission, partial remission, stable disease and progressive disease were obtained in 21 cases(70.0%),4 cases(13.3%),3 cases (10.0%) and 2 cases (6.7%). Conclusion The most LMNET arise from the gut, and the CEUS scan showoverall and uniform enhancement, with obvious subside at portal vein phase. The short-term efficacy by MWA ispromising.

Key words: Neuroendocrine tumors, Liver metastasis, Contrast-enhanced ultrasound, Microwave ablation, Therapy

吕莉, 刘苗, 周敏, 王波玲. 30例肝转移性神经内分泌肿瘤超声造影表现及微波消融治疗效果分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 777-780.

Lyu Li, Liu Miao, Zhou Min, et al. Contrast-enhanced ultrasound feature and short-term efficacy of microwave ablation in patients with neuroendocrine tumor liver metastases: An analysis of 30 cases[J]. Journal of Practical Hepatology, 2024, 27(5): 777-780.

参考文献

[1] Chan MY, Ma KW, Chan A. Surgical management of neuroendocrine tumor-associated liver metastases: a review. Gland Surg, 2018, 7(1): 28-35.
[2] Keutgen XM, Schadde E, Pommier RF, et al. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Semin Oncol, 2018, 45(4): 232-235.
[3] Ronot M, Clift AK, Baum RP, et al. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology, 2018, 106(1): 74-88.
[4] Barat M, Soyer P, Al Sharhan F, et al. Magnetic resonance imaging may be able to identify the origin of neuroendocrine tumor liver metastases. Neuroendocrinology, 2021, 111(11): 1099-1110.
[5] Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother, 2021, 22(6): 685-693.
[6] Zhang JZ, Li S, Zhu WH, et al. Microwave ablation combined with hepatectomy for treatment of neuroendocrine tumor liver metastases. World J Clin Cases, 2021, 9(19): 5064-5072.
[7] 梁娴, 符慧, 黄利. 超声造影在肝转移性神经内分泌肿瘤鉴别诊断及引导消融治疗中的应用价值. 临床超声医学杂志, 2022, 24(6): 427-430.
[8] 中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版). 中国癌症杂志, 2022, 32(6): 545-580.
[9] Ruzzenente A, Bagante F, Bertuzzo F, et al. Liver resection for neuroendocrine tumor liver metastases within Milan criteria for liver transplantation. J Gastrointest Surg, 2019, 23(1): 93-100.
[10] Huh J, Park J, Kim KW, et al. Optimal phase of dynamic computed tomography for reliable size measurement of metastatic neuroendocrine tumors of the liver: Comparison between pre- and post-contrast phases. Korean J Radiol, 2018, 19(6): 1066-1076.
[11] 妥子君, 郭建英, 李振妍. 超声造影在肝脏神经内分泌肿瘤诊断中的应用价值. 肝脏, 2020, 25(6): 640-643.
[12] Walczyk J, Sowa-Staszczak A. Diagnostic imaging of gastrointestinal neuroendocrine neoplasms with a focus on ultrasound. J Ultrason, 2019, 19(78): 228-235.
[13] 尹珊珊, 姜彬彬, 崔秋丽, 等. 神经内分泌肿瘤肝转移超声造影表现与分化程度的关系初探. 中华超声影像学杂志, 2019, 28(2): 109-114.
[14] 严华.超声造影在诊断肝脏转移性神经内分泌肿瘤中的价值. 肝脏, 2019, 24(8): 902-904.
[15] Maleux G, Izamis ML, Werbrouck C, et al. Characterization of liver metastases during catheter-directed liver interventions: A comparison between dual phase cone-beam computed tomography and conventional contrast-enhanced computed tomography. J Belg Soc Radiol, 2020, 104(1): 41.
[16] Barachini O, Bernt R, Mirzaei S, et al. The impact of¹⁸F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract. BMC Med Imaging, 2020, 20(1): 22.
[17] Hayoz R, Vietti-Violi N, Duran R, et al. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol, 2020, 30(12): 6593-6602.
[18] Meloni MF, Francica G, Chiang J, et al. Use of contrast-enhanced ultrasound in ablation therapy of HCC: Planning, guiding, and assessing treatment response. J Ultrasound Med, 2021, 40(5): 879-894.
[19] Barr RG, Huang P, Luo Y, etal. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid. Abdom Radiol, 2020, 45(11): 3779-3788.
[20] Cao J, Fan P, Wang F, et al. Application of contrast-enhanced ultrasound in minimally invasive ablation of benign thyroid nodules. J Interv Med, 2022, 5(1): 32-36.

30例肝转移性神经内分泌肿瘤超声造影表现及微波消融治疗效果分析^*

Contrast-enhanced ultrasound feature and short-term efficacy of microwave ablation in patients with neuroendocrine tumor liver metastases: An analysis of 30 cases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[2]	张志强, 方坚, 李东良. 介入治疗肝硬化门静脉高压症研究进展与挑战^*[J]. 实用肝脏病杂志, 2024, 27(5): 650-653.
[3]	中国医药生物技术协会慢病管理分会肝病学组. 双环醇防治肝脏炎性损伤多学科专家共识[J]. 实用肝脏病杂志, 2024, 27(5): 659-668.
[4]	彭麟, 杨春, 李兴泉. 聚乙二醇干扰素α-2b联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 677-680.
[5]	冉书容, 刘洋, 雷兰. 恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 681-684.
[6]	黎防, 杨宏飞, 张青. 索非布韦联合雷迪帕韦治疗慢性丙型肝炎患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(5): 685-688.
[7]	刘雅光, 胡连智, 董一侠, 刘洋. 抗病毒治疗的基因1b型慢性丙型肝炎患者疗效及其血清γ-干扰素和白细胞介素-10水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 689-692.
[8]	莫伟斌, 张清友, 黄晓涵, 欧阳婉爱. 达诺瑞韦联合拉维达韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 693-696.
[9]	高怡, 沈小雪, 夏素芹, 张洁, 朱先兰. 自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(5): 709-712.
[10]	蒋叶舟, 花霞, 陈国飞, 朱青蓝, 蔡明月. 自身免疫性肝炎患者血清瘦素、外周血调节性T细胞和Th17细胞水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 713-716.
[11]	朱家瑞, 葛绍锋, 叶桂云, 黄远茂. 自身免疫性肝炎患者外周血NLR和nCD64指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 717-720.
[12]	王燕燕, 周桐桐, 卞兆连. 原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 721-724.
[13]	王秀娟, 朱贺, 张茹梦, 常文绘, 刘玉玉. 泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者不同减量方法的效果研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 729-732.
[14]	李瑞妮, 王莎莎, 贾泽博, 韦晓洁, 王腾. 聚桂醇和蛇毒血凝酶注射配合内镜下套扎治疗乙型肝炎肝硬化并发EVB患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 741-744.
[15]	田琳, 康颖, 崔洁, 石颖鹏. 内镜下套扎联合奥曲肽和凝血酶治疗肝硬化并发食管胃静脉曲张出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 745-748.